Viewing Study NCT05276713



Ignite Creation Date: 2024-05-06 @ 5:20 PM
Last Modification Date: 2024-10-26 @ 2:27 PM
Study NCT ID: NCT05276713
Status: UNKNOWN
Last Update Posted: 2022-03-11
First Post: 2022-03-03

Brief Title: Outcome of Tucidinostat-Based Therapy in HR Metastatic Breast Cancer Patients Previously Treated With CDK46 Inhibitor
Sponsor: Beijing 302 Hospital
Organization: Beijing 302 Hospital

Study Overview

Official Title: A Single-center Study of the Outcome of Tucidinostat-Based Therapy in Hormone Receptor-Positive Metastatic Breast Cancer Patients Previously Treated With CDK46 Inhibitor Therapy
Status: UNKNOWN
Status Verified Date: 2022-03
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: To evaluate the efficacy of tucidinostat-based therapy in hormone receptor-positive metastatic breast cancer patients previously treated with CDK46 inhibitor therapy in the real world
Detailed Description: Cyclin-dependent kinase CDK 46 inhibitors have changed the treatment pattern of patients with hormone receptor-positive HER2-negative advanced breast cancer significantly prolongling patientsPFS and OSbut there is no optimal therapy after its progressionTucidinostat formerly known as chidamide is an oral subtype-selective histone deacetylase inhibitor ACE trial demonstrated that tucidinostat plus exemestane improved PFS compared with placebo plus exemestane in HRMBC patients that progressed after previous endocrine therapyonly 7 patients enrolled in the trial had previously received CDK46 inhibitorsThe aim of this trial is to evaluate the efficacy of tucidinostat-based therapy in hormone receptor-positive metastatic breast cancer patients previously treated with CDK46 inhibitor therapy in the real world

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None